These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15132714)

  • 21. Interaction of rofecoxib and celecoxib with warfarin.
    Schaefer MG; Plowman BK; Morreale AP; Egan M
    Am J Health Syst Pharm; 2003 Jul; 60(13):1319-23. PubMed ID: 12901032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS; Nourjah P; Grosser SC; Graham DJ
    Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
    Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA
    Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
    Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.
    Micklewright R; Lane S; Linley W; McQuade C; Thompson F; Maskrey N
    Aliment Pharmacol Ther; 2003 Feb; 17(3):321-32. PubMed ID: 12562444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
    Graham DJ; Campen D; Hui R; Spence M; Cheetham C; Levy G; Shoor S; Ray WA
    Lancet; 2005 Feb 5-11; 365(9458):475-81. PubMed ID: 15705456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
    Reicin AS; Shapiro D; Sperling RS; Barr E; Yu Q
    Am J Cardiol; 2002 Jan; 89(2):204-9. PubMed ID: 11792343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular events and COX-2 inhibitors.
    Fleming M
    JAMA; 2001 Dec; 286(22):2808; author reply 2811-2. PubMed ID: 11735742
    [No Abstract]   [Full Text] [Related]  

  • 30. Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database.
    Lugardon S; Lapeyre-Mestre M; Montastruc JL
    Eur J Clin Pharmacol; 2004 Nov; 60(9):673-7. PubMed ID: 15517227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports.
    Sanchez-Matienzo D; Arana A; Castellsague J; Perez-Gutthann S
    Clin Ther; 2006 Aug; 28(8):1123-1132. PubMed ID: 16982289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Improper use of selective COX-2 inhibitor NSAIDs].
    Rocamora Batalla M; Vallano Ferraz A
    Aten Primaria; 2002 Feb; 29(2):122. PubMed ID: 11844430
    [No Abstract]   [Full Text] [Related]  

  • 37. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.
    Layton D; Marshall V; Boshier A; Friedmann P; Shakir SA
    Drug Saf; 2006; 29(8):687-96. PubMed ID: 16872242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme.
    Harrison-Woolrych M; Herbison P; McLean R; Ashton J; Slattery J
    Drug Saf; 2005; 28(5):435-42. PubMed ID: 15853444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.
    Whelton A; Fort JG; Puma JA; Normandin D; Bello AE; Verburg KM;
    Am J Ther; 2001; 8(2):85-95. PubMed ID: 11304662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.